| Serpin Neuroprotection | |
|---|---|
| Protein Family | Serine protease inhibitors (SERPINs) |
| Key Members | SERPINA1, SERPINA3, SERPINE1, SERPINA3 |
| Primary Function | Protease inhibition, neuroprotection |
| Disease Relevance | AD, PD, ALS, stroke |
The serpin (serine protease inhibitor) family comprises a diverse group of proteins that play critical roles in regulating protease activity throughout the body. In the central nervous system, serpins have emerged as important modulators of neuroinflammation, protein aggregation, and neuronal survival. Several serpin family members, including alpha-1-antichymotrypsin (SERPINA3), alpha-1-antitrypsin (SERPINA1), plasminogen activator inhibitor-1 (SERPINE1/PAI-1), and neuroserpin (SERPINA1), have been implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and stroke[1].
This page explores the multifaceted roles of serpins in neurodegeneration, their mechanisms of action, therapeutic potential, and current research directions.
SERPINs are a family of proteins characterized by a conserved tertiary structure consisting of:
The unique "spring-loaded" mechanism of serpin inhibition involves:
Multiple serpin family members are expressed in the brain:
| Serpin | Primary CNS Expression | Main Function |
|---|---|---|
| SERPINA1 (α1-antitrypsin) | Astrocytes, neurons | Protease inhibition, anti-inflammatory |
| SERPINA3 (α1-antichymotrypsin) | Astrocytes, microglia | Aβ interaction, neuroinflammation |
| SERPINE1 (PAI-1) | Endothelium, neurons | Fibrinolysis, cell survival |
| SERPINA1 (Neuroserpin) | Neurons | Synaptic plasticity, neuroprotection |
SERPINA3 is one of the most extensively studied serpins in Alzheimer's disease pathogenesis:
Expression Patterns:
Pathogenic Mechanisms:
Amyloid Interaction: SERPINA3 directly binds to amyloid-beta (Aβ) peptides, promoting their aggregation into neurotoxic oligomers and plaques. The serpin-Aβ complex is a major component of amyloid plaques in AD brains[3].
Chymotrypsin Inhibition: SERPINA3 inhibits chymotrypsin-like serine proteases, altering the proteolytic balance in the brain. Dysregulated protease activity contributes to neuronal dysfunction[4].
Neuroinflammation: SERPINA3 modulates neuroinflammatory responses through:
Genetic Associations:
Therapeutic Implications:
SERPINA1 has dual roles in AD:
Neuroprotective Functions:
Pathogenic Aspects:
Plasminogen activator inhibitor-1 plays complex roles in AD:
Mechanisms:
Therapeutic Potential:
Emerging evidence suggests SERPINA1 may be protective in PD:
Mechanisms:
Clinical Observations:
SERPINA3 expression is altered in PD:
Neuroserpin, primarily expressed in neurons, has protective functions:
SERPINA1 has been implicated in ALS pathogenesis:
PAI-1 is elevated in ALS:
SERPINA3 plays complex roles in ischemic injury:
Acute Phase Response:
Therapeutic Targeting:
PAI-1 is significantly elevated after stroke:
SERPINA1 levels are altered in stroke:
Serpins modulate neuroinflammation through multiple pathways:
Several serpins promote neuronal survival:
Serpins contribute to proteostasis:
Some serpins support neuronal health:
Strategies:
Challenges:
Approaches:
Neuroprotective Strategies:
Emerging Approaches:
| Serpin | Disease | Biomarker Potential |
|---|---|---|
| SERPINA3 | AD | CSF and plasma levels, genetic variants |
| SERPINE1 | Stroke | Prognostic marker, recurrence risk |
| SERPINA1 | PD | Serum levels, disease progression |
| SERPINA3 | ALS | Biomarker for disease progression |
Cheng Q et al. Neuroserpin: structure, function, and therapeutic potential. Cell Mol Neurobiol. 2018
Kinghorn KJ et al. Neuroserpin and Alzheimer's disease. J Alzheimers Dis. 2016
Soeda Y et al. SERPINA3 mediates amyloid-beta clearance in microglia. J Neurosci Res. 2020
Yang L, Wang Y, Li L, et al. The serpin family and neurodegeneration: mechanisms and therapeutic targets. Progress in Neurobiology. 2015. ↩︎
Giannakopoulos P, Bouras C, Greco A, et al. SERPINA3 expression in human brain during aging and in Alzheimer's disease. Brain Research. 1998. ↩︎
Baker C, Belbin O, Ferrari L, et al. SERPINA3 in Alzheimer's disease: a candidate gene and potential therapeutic target. Journal of Neurology, Neurosurgery & Psychiatry. 2007. ↩︎
Jurinke C, van den Boom D, Zeller M, et al. SERPINA3 (alpha-1-antichymotrypsin): an emerging biomarker for Alzheimer's disease. Expert Opinion on Therapeutic Targets. 2005. ↩︎
Abraham CR, Yao J, Rohn B, et al. The role of alpha-1-antichymotrypsin in neuroinflammation and Alzheimer's disease. Annals of the New York Academy of Sciences. 2001. ↩︎
Benussi L, Ghidoni R, Binetti G, et al. Alpha-1-antichymotrypsin signal peptide variant and risk of Alzheimer's disease. Neurobiology of Aging. 2013. ↩︎
Soeda Y, Watanabe R, Koyama T, et al. SERPINA3 mediates amyloid-beta clearance in microglia. Journal of Neuroscience Research. 2020. ↩︎
Koster TP, Luchtman D, Maat-Schieman M, et al. Serpinina1/alpha1-antitrypsin as biomarker in experimental models of neurodegeneration. Journal of Neural Transmission. 2013. ↩︎
Elsasser S, Gotte M, Bertsch W, et al. SERPINE1/PAI-1 in neurodegenerative processes of the central nervous system. Journal of Neurology. 2009. ↩︎
Tatom JB, Wang H, Krishnan B, et al. Plasminogen activator inhibitor-1 (PAI-1) in Alzheimer's disease: role in pathogenesis and therapeutic potential. Journal of Alzheimer's Disease. 2011. ↩︎
Ma C, Zheng M, Wang Z, et al. SERPINA1 protects dopaminergic neurons from oxidative stress in Parkinson's disease. Cell Death & Disease. 2019. ↩︎
Liep I, Hutter J, Kossmehl P, et al. SERPINA3 as a neuroprotective factor in cerebral ischemia. Journal of Cerebral Blood Flow & Metabolism. 2008. ↩︎
Simoni M, Giannini G, Verrillo L, et al. Targeting serpins in neurodegeneration: challenges and opportunities. Drug Discovery Today. 2019. ↩︎